TY - JOUR
T1 - Sarcoma treatment in the era of molecular medicine
AU - Grünewald, Thomas G.P.
AU - Alonso, Marta
AU - Avnet, Sofia
AU - Banito, Ana
AU - Burdach, Stefan
AU - Cidre-Aranaz, Florencia
AU - Di Pompo, Gemma
AU - Distel, Martin
AU - Dorado-Garcia, Heathcliff
AU - Garcia-Castro, Javier
AU - González-González, Laura
AU - Grigoriadis, Agamemnon E.
AU - Kasan, Merve
AU - Koelsche, Christian
AU - Krumbholz, Manuela
AU - Lecanda, Fernando
AU - Lemma, Silvia
AU - Longo, Dario L.
AU - Madrigal-Esquivel, Claudia
AU - Morales-Molina, Álvaro
AU - Musa, Julian
AU - Ohmura, Shunya
AU - Ory, Benjamin
AU - Pereira-Silva, Miguel
AU - Perut, Francesca
AU - Rodriguez, Rene
AU - Seeling, Carolin
AU - Al Shaaili, Nada
AU - Shaabani, Shabnam
AU - Shiavone, Kristina
AU - Sinha, Snehadri
AU - Tomazou, Eleni M.
AU - Trautmann, Marcel
AU - Vela, Maria
AU - Versleijen-Jonkers, Yvonne M.H.
AU - Visgauss, Julia
AU - Zalacain, Marta
AU - Schober, Sebastian J.
AU - Lissat, Andrej
AU - English, William R.
AU - Baldini, Nicola
AU - Heymann, Dominique
PY - 2020/11/6
Y1 - 2020/11/6
N2 - Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.
AB - Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.
KW - bone sarcoma
KW - molecular diagnostics
KW - molecular medicine
KW - soft tissue sarcoma
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85092390651&partnerID=8YFLogxK
U2 - 10.15252/emmm.201911131
DO - 10.15252/emmm.201911131
M3 - Review article
AN - SCOPUS:85092390651
SN - 1757-4676
VL - 12
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 11
M1 - e11131
ER -
